

CURRENT RESEARCH TOPICS IN PHARMACY: *Therapeutic Drug Monitoring*

March 29th, 2023 13.00 PM ISTANBUL



FOR REGISTRATION:

First Session- Moderator: Esra TATAR 13.00-14.30 PM

Welcome- Prof. Mesut Sancar
Marmara University, Istanbul, Türkiye

Analytical techniques used for therapeutic drug monitoring – Dr.Mohd Younis Rather
Government Medical College Srinagar, Srinagar, India

Combination of therapeutic drug monitoring and genotyping in pharmacotherapy- Prof.Halit Sinan Süzen
Ankara University, Ankara Türkiye

Therapeutic drug monitoring of antipsychotics – Assist.Prof.Ana V. Pejic
University of Kragujevac, Kragujevac, Serbia

Second Session – Moderator: Betül OKUYAN 15:00-16.30 PM

How to avoid perils and pitfalls when reading epidemiological studies– Dr.Pamela Xaverius
University of Health Science and Pharmacy in St.Louis, USA

Current themes in immunosuppressive therapies: TDM research and practice -Assist.Prof.Abdikarim Abdi
Yeditepe University, Istanbul, Türkiye

TDM of antimicrobials : Role of clinical pharmacist- Assist. Prof. Emre Kara
Hacettepe University, Ankara, Türkiye

Chair

Prof. Hatice Kübra ELÇİOĞLU

Vice Chairs

Prof. Levent KABASAKAL & Assoc. Prof. Esra TATAR

ORGANIZING & SCIENTIFIC COMMITTEE

Editorial Board of Journal of Research in Pharmacy
<https://www.jresopharm.com/>

JRP

Journal of Research in Pharmacy

An international open-access journal of pharmacy and pharmaceutical sciences
Formerly published as Marmara Pharmaceutical Journal

ONLINE
SYMPOSIUM

CURRENT RESEARCH TOPICS IN PHARMACY: *Therapeutic Drug Monitoring*

March 29th, 2023 13.00 PM ISTANBUL

ORGANIZING & SCIENTIFIC COMMITTEE

Editorial Board of Journal of Research in Pharmacy

<https://www.jrespharm.com/>

Esra Tatar
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Türkiye

Levent Kabasakal
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Türkiye

Ayşe Nur Hazar Yavuz
(Secretary)
Marmara University, Istanbul, Türkiye

Abdikarim Mohammed Abdi
Yeditepe University, Istanbul, Türkiye

Afiye Büşra Uğur Kaplan
Atatürk University, Erzurum, Türkiye

Ahmet Emir
Ege University, Izmir, Türkiye

Ali Demir Sezer
Marmara University, Istanbul, Türkiye

Ammad Ahmad Farooqi
Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan

Ana V. Pejić
University of Kragujevac, Kragujevac, Serbia

Anil Kumar Dwivedi
Central Drug Research Institute, Lucknow, India

Anisa Elhamili
University of Tripoli, Tripoli, Libya

Annalisa Chiavaroli
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Antoaneta Trendafilova
Bulgarian Academy of Sciences, Sofia, Bulgaria

Ayça Toprak Semiz
Giresun University, Giresun, Türkiye

Ayfer Beceren
Marmara University, Istanbul, Türkiye

Ayşe Esra Karadağ
Istanbul Medipol University, Istanbul, Türkiye

Aysenur Günaydin Akıldiz
Bezmi Alem Vakıf University, Istanbul, Türkiye

Bahadır Bülbül
Düzce University, Düzce, Türkiye

Betul Okuyan
Marmara University, Istanbul, Türkiye

Beza Ecem Öz Bedir
Ankara Yıldırım Bayezit University, Ankara, Türkiye

Burcu Üner
The University of Health Science and Pharmacy in St. Louis, USA

Büşra Ertas
Marmara University, Istanbul, Türkiye

Ceren Emir
Ege University, Izmir, Türkiye

Claudio Ferrante
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Debora Dummer Meira
Federal University of Espirito Santo, Vitória-Espirito Santo, Brazil

Derya Özşavcı
Marmara University, Istanbul, Türkiye

Dhanashree P. Sanap
Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, India

Dinesh Kumar
Indian Institute of Technology (IIT), Varanasi, India

Ebru Altıntaş
Istanbul University, Istanbul, Türkiye

Ela Hoti
University of Medicine, Tirana, Albania

Emine Terzi
Ankara Yıldırım Bayezit University, Ankara, Türkiye

Emirhan Nemutlu
Hacettepe University, Ankara, Türkiye

Emrah Özakar
Atatürk University, Erzurum, Türkiye

Enkelejda Goci
Aldent University, Tirana, Albania

Entela Halocli
University of Medicine, Tirana, Albania

Erkan Rayaman
Marmara University, Istanbul, Türkiye

Fatima Missoun
University of Mostaganem, Mostaganem, Algeria

Gizem Tatar Yılmaz
Karadeniz Technical University, Trabzon, Türkiye

Gülberk Uçar
Hacettepe University, Ankara, Türkiye

Gülşin Tınaz
Marmara University, Istanbul, Türkiye

Gülşah Gedik
Trakya University, Edirne, Türkiye

Haidar A. Abdulamir
Al-Maaqil University, Basra, Iraq

Hamide Sena Özbay
Hacettepe University, Ankara, Türkiye

Hasan Erdiçin Sellitepe
Karadeniz Technical University, Trabzon, Türkiye

İ. İrem Tatlı Çankaya
Hacettepe University, Ankara, Türkiye

Karem Buran
University of Health Sciences, Istanbul, Türkiye

Klevo Shpati
Albanian University, Tirana, Albania

Klodiola Dhano
Aldent University, Tirana, Albania

Laleh Khodae
Tabriz University of Medical Sciences, Tabriz, Iran

Lejla Klepo
University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Lokman Ayaz
Trakya University, Edirne, Türkiye

Lorena Memushaj
Aldent University, Tirana, Albania

Maja Ortner Hadžiabdić
University of Zagreb, Zagreb, Croatia

Mehmet Gümüştas
Ankara University, Ankara, Türkiye

Merve Kabasakal
University of Health Sciences, Istanbul, Türkiye

Mesut Sancar
Marmara University, Istanbul, Türkiye

Mirela Miraçlı
University of Medicine, Tirana, Albania

Mirjana Marčetić
University of Belgrade, Belgrade, Serbia

Mohd Younis Rather
Government Medical College Srinagar, Srinagar, India

Murat Doğan
Cumhuriyet University, Sivas, Türkiye

Nurhan Tekin
University of Health Sciences, Istanbul, Türkiye

Nurettin Yaylı
Karadeniz Technical University, Trabzon, Türkiye

Ongun Mehmet Saka
Ankara University, Ankara, Türkiye

Oya Kerimoğlu
Marmara University, Istanbul, Türkiye

Pablo Miralles Ibarra
University of Valencia, Burjassot, Spain

Pankaj Dwivedi
The University of Health Science and Pharmacy in St. Louis, USA

Patricia Rijo
Lusofona University, Lisbon, Portugal

Pinar Talay Pinar
Yüzüncü Yıl University, Van, Türkiye

Renuka Khatik
Washington University in St. Louis, USA

Rezarta Shkrelli
Aldent University, Tirana, Albania

Rukiye Sevinç Özakar
Atatürk University, Erzurum, Türkiye

Rümeysa Keleş Kaya
Sakarya University, Sakarya, Türkiye

Saeideh Soltani
Isfahan University of Medical Sciences, Isfahan, Iran

Sakine Tuncay Tanrıverdi
Ege University, Izmir, Türkiye

Simone Carradori
G. d'Annunzio University of Chieti-Pescara, Chieti, Italy

Sinan Sermet
Istanbul Arel University, Istanbul, Türkiye

Sneha Agrawal
Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, Maharashtra, India

Somaieh Soltani
Tabriz University of Medical Sciences, Tabriz, Iran

Tarık Catić
Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

Turgut Taşkın
Marmara University, Istanbul, Türkiye

Uğur Karagöz
Trakya University, Edirne, Türkiye

Ünzile Yaman
Katip Çelebi University, Izmir, Türkiye

Viktorija Maksimova
Goce Delcev University, Stip, Republic of N. Macedonia

Vildan Çeliksöy
Cardiff University, Cardiff, UK

Vilma Toska Papajani
University of Medicine, Tirana, Albania

Yeliz Şahin
Ağrı İbrahim Çeçen University, Ağrı, Türkiye

Zahraa Amer Hashim
Mosul University, Mosul, Iraq

Zeina Althanoon
Mosul University, Mosul, Iraq

Zoran Zeković
University of Novi Sad, Novi Sad, Serbia

JRP

Journal of Research in Pharmacy

An international open-access journal of pharmacy and pharmaceutical sciences

Formerly published as Marmara Pharmaceutical Journal

ONLINE
SYMPOSIUM

THERAPEUTIC DRUG MONITORING OF ANTIPSYCHOTICS

Ana V. PEJČIĆ 

Department of Pharmacology and Toxicology, Faculty of Medical Sciences,
University of Kragujevac, Kragujevac, Serbia

anapejic201502@yahoo.com

Antipsychotics are drugs that are primarily used in the management of schizophrenia and other disorders with psychotic features [1]. There are many antipsychotics available for clinical use [2]. They are traditionally divided into two groups based on the receptor-binding profile, incidence of extrapyramidal side effects and efficacy against negative symptoms: first-generation (also known as 'typical', 'classical' or 'conventional') antipsychotics such as haloperidol and chlorpromazine, and second-generation antipsychotics (also known as 'atypical' antipsychotics) such as clozapine, risperidone and aripiprazole [1, 2]. Therapeutic drug monitoring (TDM) refers to the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy [3, 4]. TDM has a long history in psychiatry, but routine TDM of antipsychotics has not yet been universally accepted as a standard clinical practice [3, 4]. In 2020, the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the German Association of Neuropsychopharmacology and Pharmacopsychiatry published a joint consensus statement with the aim to assist clinicians who regularly prescribe antipsychotics to effectively implement TDM of antipsychotics in their clinical practice [4]. The consensus statement provides four levels of recommendations regarding TDM for specific antipsychotics, their therapeutic reference range in blood and laboratory alert level (threshold level above which the risk for adverse drug reactions is expected to increase) [4]. Antipsychotics for which TDM is strongly recommended (level 1 recommendation) include clozapine, fluphenazine, haloperidol, olanzapine, perazine and perphenazine [4]. For these drugs, blood level within the therapeutic range is associated with favorable clinical outcomes in terms of efficacy, as well as safety and tolerability [4]. For aripiprazole, chlorpromazine, flupenthixol, paliperidone, quetiapine, risperidone, sertindole, and ziprasidone, there are fewer data linking therapeutic blood level ranges to benefit or harm, so TDM is recommended, but with a lower level of clinical confidence (level 2 recommendation) [4]. For brexpiprazole, cariprazine, chlorprothixene, iloperidone, loxapine, lurasidone, melperone, and pimozide, TDM is considered to be useful (level 3 recommendation), but the evidence is less supportive (the link between blood level and clinical effects has not been addressed yet or only retrospectively or in single case reports, so there is a need for more data) [4]. For asenapine, there is no available evidence associating clinical effects and blood level, so TDM is only considered potentially useful (level 4 recommendation) [4]. In addition, TDM is strongly recommended for a number of specific indications regardless of the level of recommendation for any particular antipsychotic [4]. These indications include, for

example, uncertain adherence to antipsychotics, lack of clinical response within established therapeutic dose ranges, recurrence or relapse of symptoms during maintenance treatment, adverse drug reactions, concomitant use of medications which may interfere with the metabolism of antipsychotics, specific patient populations (e.g. patients with abnormally high or low body weight or body mass index, pregnant patients, lactating patients, children, adolescents, elderly, patients with intellectual disabilities, patients with hepatic or renal dysfunction, patients with severe cardiovascular disease...), switching between the original and generic forms of antipsychotics, switching between oral antipsychotics and long-acting injectable antipsychotics (LAIs), et cetera [4]. Blood sample should be taken at steady-state [4]. Appropriate sampling time during stable dosing of oral formulations is considered to be immediately before intake of the morning dose, i.e. 24 hours after the last dose if the antipsychotic is given once daily in the morning (for drugs taken in the evening the blood draw interval is 12 hours) or immediately before the next injection for LAIs [4]. It should be noted that the therapeutic reference ranges given in the consensus statement are an orienting, population-based tool that may not always be applicable to all patients, that they are derived mainly from studies on oral antipsychotics and that they apply to the primary/specific indication of antipsychotics (schizophrenia) [4]. The following information is needed for adequate interpretation of antipsychotic blood level: demographic and clinical characteristics of the patient, comedications, indication for the TDM request, formulation of the antipsychotic, time point of the blood draw, time since the last dose change, and clinical information regarding symptom severity and response or remission, as well as adverse drug reactions [4]. Despite the promise of TDM to improve the effectiveness and safety of antipsychotics in clinical practice, some limitations should be acknowledged: (A) Therapeutic blood level ranges are derived from groups of patients who agree to be studied and their data may not generalize to usual care patients who have more comorbidities and receive multiple medications; (B) Blood level ranges of antipsychotics are almost exclusively derived from patients with schizophrenia, so more data should be collected for many other approved and off-label indications of antipsychotics; (C) TDM results are only helpful if blood sample is obtained at an appropriate time and sufficient contextual information is available; (D) There is a need for more data regarding relationship between blood level ranges for many specific antipsychotics and clinical efficacy and tolerability, as well as for more evidence in specific populations of patients (e.g. elderly, children, adolescents); (E) Lack of laboratories for TDM and costs may be significant barriers for implementing TDM of antipsychotics in some clinical care settings [4]. Despite these limitations which could mostly be addressed by additional research, TDM has the potential to become a valuable tool for solving problems in antipsychotic treatment and improving efficacy and safety of antipsychotics in clinical practice [3, 4].

Keywords: Therapeutic drug monitoring; antipsychotics; recommendations.

REFERENCES

- [1] Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. *Br Med Bull.* 2015; 114(1): 169-179. [\[CrossRef\]](#)
- [2] Ritter JM, Flower RJ, Henderson G, Loke YK, MacEwan D, Rang HP, Rang and Dale's Pharmacology, ninth ed., Elsevier, Edinburgh 2020.
- [3] Dadiomov D. Therapeutic drug monitoring of antipsychotics. *Curr Psychiatry.* 2020; 19(2): 40: 45-46.
- [4] Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gründer G; American Society of Clinical Psychopharmacology. The Therapeutic Drug Monitoring Task Force of The Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. *J Clin Psychiatry.* 2020; 81(3): 19cs13169. [\[CrossRef\]](#)